去纤苷（defiteli）用法用量

On March 30, 2016, the FDA approved defibrotide (defiteli) for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstructive syndrome (SOS), and renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT). So far, many patients are still unclear about the usage and dosage of defibrotide (defiteli). Let me introduce it to you below!

The recommended dose of defibrotide (defiteli) for adult and pediatric patients is 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. The dose should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT preparation protocol. Give defibrotide (defiteli) for a minimum of 21 days. If signs and symptoms of hepatic VOD do not resolve after 21 days, continue defibrination until resolution of VOD or up to a maximum of 60 days. 

Defibrotide (defiteli) may enhance the pharmacodynamic activity of antithrombotic/fibrinolytic agents such as heparin or alteplase. Concomitant use of defibrotide (defiteli) with antithrombotic or fibrinolytic drugs is contraindicated due to increased risk of bleeding.

The recommended dose of defibrotide (defiteli) is 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. Treatment lasts for a minimum of 21 days. If signs and symptoms of VOD do not resolve after 21 days, continue treatment until resolution. Hypersensitivity reactions have occurred in less than 2% of patients treated with defibrotide (defiteli). These reactions include rash, urticaria, and angioedema. If a severe hypersensitivity reaction occurs, discontinue defiteli, treat with standard medical care, and monitor until symptoms resolve. 

The usage and dosage of defibrotide (defiteli sodium, defiteli) are as above. If the patient has other questions, please consult the medical companion.